EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma

Beatrice Seddon, Franel Le Grange, Rita Simões, Chris Stacey, Shumona Shelly, Sharon Forsyth, Laura White, Charles Candish, Peter Dickinson, Aisha Miah, Syed Ali Moinuddin, James Wylie und 1 weitere

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2024.05.024 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Beatrice Seddon und 12 weiteren Autor:innen. Beteiligte Einrichtung: London Sarcoma Service, Department of Oncology, University College Hospital, London, United Kingdom. Electronic address: ctc.imris@ucl.ac.uk. Hauptthemen laut MEDLINE: Radiotherapy, Intensity-Modulated, Sarcoma, Extremities. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Primary soft tissue sarcoma (STS) is rare, with many tumors occurring in extremities. Local management is limb-sparing surgery and preoperative/postoperative radiation therapy (RT) for patients at high risk of local recurrence. We prospectively investigated late normal tissue toxicity and limb function observed after intensity modulated RT (IMRT) in extremity STS. METHODS AND MATERIALS: Patients with extremity STS, age ≥16 years. Two treatment cohorts: IMRT 50 Gy in 25 × 2 Gy fractions (preoperative) or 60/66 Gy in 30/33 × 2 Gy fractions (postoperative). The primary endpoint was the rate of grade ≥2 late soft tissue fibrosis (subcutaneous tissue) at 24 months after IMRT (Radiation Therapy Oncology Group late radiation morbidity scoring). RESULTS: One hundred sixty-eight patients were registered between March 2016 and July 2017. Of those, 159 (95%) received IMRT (106, 67% preoperative RT; and 53, 33% postoperative RT) with a median follow-up of 35.2 months (IQR, 32.9-36.6); 62% men, median age 58 years. Of 111 patients assessable for the primary endpoint at 24 months, 12 (10.8%; 95% CI, 5.7%-18.1%) had grade ≥2 subcutaneous fibrosis. The overall rate at 24 months of Radiation Therapy Oncology Group late skin, bone, and joint toxicity was 7 of 112 (6.3%), 3 of 112 (2.7%), and 10 of 113 (8.8%), respectively, and for Stern's scale edema was 6 of 113 (5.3%). More wound complications were observed with preoperative than postoperative RT (29.2% vs 3.8%). Overall survival at 24 months was 84.6%, and the local recurrence event rate at 24 months was 10%. CONCLUSIONS: The rate of grade ≥2 subcutaneous fibrosis at 24 months after IMRT was 10.8%, consistent with other recent trials of IMRT and lower than historically reported rates in patients treated with 3-dimensional conformal RT. This trial provides further evidence for the benefits of IMRT in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Radiotherapy, Intensity-ModulatedSarcomaExtremitiesHumansMiddle AgedMaleFemaleAgedAdultProspective StudiesFibrosisRadiation InjuriesDose Fractionation, RadiationOrgans at RiskNeoplasm Recurrence, Local

Autor:innen und Institutionen

  • London Sarcoma Service, Department of Oncology, University College Hospital, London, United Kingdom. Electronic address: ctc.imris@ucl.ac.uk.
  • London Sarcoma Service, Department of Oncology, University College Hospital, London, United Kingdom.
  • National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, London, United Kingdom.
  • Radiotherapy Physics Department, University College Hospital, London, United Kingdom.
  • Cancer Research UK & University College London Cancer Trials Centre, London, United Kingdom.
  • Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, United Kingdom.

Förderung

  • Cancer Research UK

Zitieren

APA

Seddon, B., Grange, F. L., Simões, R., Stacey, C., Shelly, S., Forsyth, S., White, L., Candish, C., Dickinson, P., Miah, A., Moinuddin, S. A., Wylie, J., & Lopes, A. (2024). The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.05.024

Vancouver

Seddon B, Grange FL, Simões R, Stacey C, Shelly S, Forsyth S, et al. The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.05.024

BibTeX
@article{Seddon2024,
  author = {Seddon, Beatrice and Grange, Franel Le and Simões, Rita and Stacey, Chris and Shelly, Shumona and Forsyth, Sharon and White, Laura and Candish, Charles and Dickinson, Peter and Miah, Aisha and Moinuddin, Syed Ali and Wylie, James and Lopes, Andre},
  title = {The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2024.05.024}
}
Kostenlos starten →